insight
✂️ 성형 🏥 중증 탈모 한방 반려 게놈 🌐 전체
← 뒤로

Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.

🦱 탈모
4/5 보강
The Journal of clinical endocrinology and metabolism 📖 저널 OA 45.7% 2021: 18/25 OA 2022: 28/59 OA 2023: 22/59 OA 2024: 31/77 OA 2025: 83/152 OA 2026: 45/83 OA 2021~2026 2004 Vol.89(5) p. 2179-84 피인용 38회 cited 475 RCR 10.18 Urinary Bladder and Prostate Researc
TL;DR Dutasteride appeared to be well tolerated with an adverse event profile similar to placebo and reduction in its level with 5alpha-reductase inhibitors improves the symptoms associated with BPH and reduces the risk of acute urinary retention and prostate surgery.
Retraction 확인
출처
PubMed DOI OpenAlex Semantic 마지막 보강 2026-05-12

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
399 patients with BPH were randomized to receive once-daily dosing for 24 wk of dutasteride (0.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Mean testosterone levels increased but remained in the normal range for all treatment groups. Dutasteride appeared to be well tolerated with an adverse event profile similar to placebo.
📑 코퍼스 인용 관계 · 인용됨 38
📑 인용한 논문 (6) ▾
연도별 인용 (2012–2026) · 합계 298
OpenAlex 토픽 · Urinary Bladder and Prostate Research Hormonal and reproductive studies Prostate Cancer Diagnosis and Treatment

Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S

📖 무료 전문 🔓 OA PDF oa
PubMed ↗ DOI ↗ BibTeX ↓ RIS ↓

Abstract

Dihydrotestosterone (DHT) is the primary metabolite of testosterone in the prostate and skin. Testosterone is converted to DHT by 5alpha-reductase, which exists in two isoenzyme forms (types 1 and 2). DHT is associated with development of benign prostatic hyperplasia (BPH), and reduction in its level with 5alpha-reductase inhibitors improves the symptoms associated with BPH and reduces the risk of acute urinary retention and prostate surgery. A selective inhibitor of the type 2 isoenzyme (finasteride) has been shown to decrease serum DHT by about 70%. We hypothesized that inhibition of both isoenzymes with the dual inhibitor dutasteride would more effectively suppress serum DHT levels than selective inhibition of only the type 2 isoenzyme. A total of 399 patients with BPH were randomized to receive once-daily dosing for 24 wk of dutasteride (0.01, 0.05, 0.5, 2.5, or 5.0 mg), 5 mg finasteride, or placebo. The mean percent decrease in DHT was 98.4 +/- 1.2% with 5.0 mg dutasteride and 94.7 +/- 3.3% with 0.5 mg dutasteride, significantly lower (P < 0.001) and with less variability than the 70.8 +/- 18.3% suppression observed with 5 mg finasteride. Mean testosterone levels increased but remained in the normal range for all treatment groups. Dutasteride appeared to be well tolerated with an adverse event profile similar to placebo.
🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • p-value P < 0.001
📝 환자 설명용 한 줄

Dutasteride appeared to be well tolerated with an adverse event profile similar to placebo and reduction in its level with 5alpha-reductase inhibitors improves the symptoms associated with BPH and red

이 논문을 인용하기

↓ .bib ↓ .ris
APA 7 Clark, R. V., Hermann, D. J., Cunningham, G. R., Wilson, T. H., Morrill, B. B., & Hobbs, S. (2004). Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.. The Journal of clinical endocrinology and metabolism, 89(5), 2179-84. https://doi.org/10.1210/jc.2003-030330
Vancouver Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. Jour. clin. endo. meta.. 2004;89(5):2179-84. doi:10.1210/jc.2003-030330
AMA 11 Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. Jour. clin. endo. meta.. 2004;89(5):2179-84. doi:10.1210/jc.2003-030330
Chicago Clark, R. V., Hermann, D. J., Cunningham, G. R., Wilson, T. H., Morrill, B. B., and Hobbs, S.. 2004. "Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor." The Journal of clinical endocrinology and metabolism 89 (5): 2179-84. https://doi.org/10.1210/jc.2003-030330
MLA 9 Clark, R. V., et al. "Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor." The Journal of clinical endocrinology and metabolism, vol. 89, no. 5, 2004, pp. 2179-84. doi:10.1210/jc.2003-030330.
PMID 15126539 ↗
DOI 10.1210/jc.2003-030330

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

인용 관계

그래프 OA 노드: 7/8 (88%) · 참조 0편 · 후속 7편

이 논문을 인용한 후속 연구 20

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🔓 OA PDF 열기